Greek for "aging eye," presbyopia is a progressive condition that causes near vision to fade with age.
Some 90 million Americans age 40 and over either have presbyopia or will develop it in the next decade, and many have had LASIK surgery to correct other vision problems earlier in their lives.
"Those Baby Boomers who were among the first to enjoy the benefits of LASIK to correct the vision problems of their youth now face the gradual reduction of near vision as they age," said Dr. Daniel S. Durrie, M.D., lead investigator of the study, who presented his findings at the AAO Annual Meeting in Chicago. "Fortunately for these post-LASIK patients, initial results from this study indicate NearVision CK may be a good treatment option."
NearVision CK is a quick (three-minute) treatment that uses radio waves, instead of a laser or a scalpel, to bring near vision back into focus without cutting or removing any tissue. Boasting one of the highest safety profiles in the refractive market, NearVision CK already has U.S. Food and Drug Administration approval for the treatment of presbyopia and hyperopia (farsightedness). Refractec is seeking expanded approval to improve near vision in post-LASIK patients. The Phase Three multicenter post-LASIK clinical trial will involve 150 patients who, other than suffering from presbyopia, had normal vision.
Greek for "aging eye," presbyopia is a progressive condition that causes near vision to fade with age.
"Those Baby Boomers who were among the first to enjoy the benefits of LASIK to correct the vision problems of their youth now face the gradual reduction of near vision as they age," said Dr. Daniel S. Durrie, M.D., lead investigator of the study, who presented his findings at the AAO Annual Meeting in Chicago. "Fortunately for these post-LASIK patients, initial results from this study indicate NearVision CK may be a good treatment option."
NearVision CK is a quick (three-minute) treatment that uses radio waves, instead of a laser or a scalpel, to bring near vision back into focus without cutting or removing any tissue. Boasting one of the highest safety profiles in the refractive market, NearVision CK already has U.S. Food and Drug Administration approval for the treatment of presbyopia and hyperopia (farsightedness). Refractec is seeking expanded approval to improve near vision in post-LASIK patients. The Phase Three multicenter post-LASIK clinical trial will involve 150 patients who, other than suffering from presbyopia, had normal vision.
SOURCE: Refractec, Inc., http://www.refractec.com